Introducing way more signals! We've added more signal sources to capture the full customer journey.

Learn More!
Fusion Pharmaceuticals

Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.

Last updated on

About Fusion Pharmaceuticals

Founded

2014

Estimated Revenue

$0-$1M

Employees

51-250

Funding / Mkt. Cap

$363M

Category

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

SIC Code

28

NAICs Code

3254

Location

City

Hamilton

State

Ontario

Country

Canada
Fusion Pharmaceuticals

Fusion Pharmaceuticals

Find your buyer within Fusion Pharmaceuticals

Tech Stack (66)

search